What is Leerink Partnrs’ Estimate for Lantheus Q1 Earnings?

Lantheus Holdings, Inc. (NASDAQ:LNTH) – Analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Lantheus in a research note issued on Tuesday, February 18th. Leerink Partnrs analyst R. Ruiz forecasts that the medical equipment provider will earn $1.32 per share for the quarter. The consensus estimate for Lantheus’ current full-year earnings is $6.01 per share. Leerink Partnrs also issued estimates for Lantheus’ Q3 2025 earnings at $1.51 EPS, Q4 2025 earnings at $1.57 EPS and FY2025 earnings at $5.77 EPS.

A number of other brokerages have also weighed in on LNTH. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. JMP Securities restated a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. The Goldman Sachs Group started coverage on shares of Lantheus in a report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price target for the company. Finally, Truist Financial reissued a “buy” rating and issued a $120.00 target price (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, Lantheus has a consensus rating of “Moderate Buy” and an average price target of $131.86.

Lantheus Price Performance

Shares of LNTH stock opened at $80.88 on Thursday. The stock’s fifty day moving average price is $90.60 and its 200 day moving average price is $97.20. Lantheus has a 1-year low of $56.06 and a 1-year high of $126.89. The company has a market cap of $5.62 billion, a price-to-earnings ratio of 13.46 and a beta of 0.44.

Insider Transactions at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the transaction, the director now owns 33,207 shares of the company’s stock, valued at $3,146,695.32. The trade was a 2.92 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Lantheus

Several institutional investors have recently made changes to their positions in LNTH. Geode Capital Management LLC increased its position in shares of Lantheus by 2.0% in the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock valued at $184,798,000 after buying an additional 32,551 shares in the last quarter. Moloney Securities Asset Management LLC purchased a new stake in Lantheus in the 3rd quarter worth $1,066,000. Massachusetts Financial Services Co. MA purchased a new stake in Lantheus in the 3rd quarter worth $25,955,000. Van ECK Associates Corp raised its position in Lantheus by 58.6% during the third quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider’s stock worth $6,469,000 after acquiring an additional 21,604 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in Lantheus by 47.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider’s stock valued at $1,041,000 after purchasing an additional 3,772 shares in the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.